Overweight Clinical Trials in Wilmington, North Carolina

7 studies are recruiting for overweight in Wilmington, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

   Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesity or overweight wit…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Accellacare - Tradd Court - Wilmington /ID# 282200, Wilmington, North Carolina

   Locations

   45 in total

   Run by

   AbbVie

   See if you can join NCT07752979 on ClinicalTrials.gov

2. A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

   The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Trial Management Associates - Wilmington - Floral Parkway, Wilmington, North Carolina

   Locations

   157 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07282600 on ClinicalTrials.gov

3. A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

   The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Accellacare - Wilmington - 1917 Tradd Court, Wilmington, North Carolina

   Locations

   187 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07392190 on ClinicalTrials.gov

4. A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

   The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes. About 950 adults will be in this study. Berobenatide will be compared to a plac…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Accellacare - Wilmington, Wilmington, North Carolina

   Locations

   50 in total

   Run by

   Pfizer

   See if you can join NCT07595549 on ClinicalTrials.gov

5. A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

   The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested or placebo, a medicine that has no active medicine in it. Whic…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   KDCILM, LLC & Accellacare US, Inc., Wilmington, North Carolina

   Locations

   36 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07745504 on ClinicalTrials.gov

6. Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

   Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calo…

   Stage

   Phase 3

   Ages

   18 to 79

   Site

   ACCOMPLISH-1 Research Site, Wilmington, North Carolina

   Locations

   71 in total

   Run by

   Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

   See if you can join NCT07654361 on ClinicalTrials.gov

7. Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

   The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants will get either Cagrilintide (the treatment being …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Accellacare, Wilmington, North Carolina

   Locations

   11 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07607587 on ClinicalTrials.gov